NCT06643000 2025-03-06Evaluating High-dose Furmonertinib with Bevacizumab and Pemetrexed for EGFRm NSCLC with Leptomeningeal MetastasisHenan Cancer HospitalPhase NA Recruiting60 enrolled
NCT05675033 2023-01-09Serplulimab Combined With Anti-VEGF Antibody in Advanced Lung AdenocarcinomaFujian Cancer HospitalPhase 2 Unknown50 enrolled